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Abstract Amodiaquine (AQ) is a 4-aminoquinoline widely used in the treatment of malaria as part of the
artemisinin combination therapy (ACT). AQ is metabolised towards its main metabolite
desethylamodiaquine mainly by cytochrome P450 2C8 (CYP2C8). CYP1A1 and CYP1B1 play a minor
role in the metabolism but they seem to be significantly involved in the formation of the short-lived
quinine-imine. To complete the genetic variation picture of the main genes involved in AQ metabolism
in the Zanzibar population, previously characterised for CYP2C8, we analysed in this study CYP1A1
and CYP1B1 main genetic polymorphisms. The results obtained show a low frequency of the
CYP1A1*2B ⁄ C allele (2.4%) and a high frequency of CYP1B1*6 (approximately 42%) followed by
CYP1B1*2 (approximately 27%) in Zanzibar islands. Genotype data for CYP1A1 and CYP1B1 show a
low incidence of fast metabolisers, revealing a relatively safe genetic background in Zanzibar’s
population regarding the appearance of adverse effects.
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Introduction
Amodiaquine (AQ), a 4-aminoquinoline, is widely used in
African national malaria control programmes mainly by
means of its combination with artesunate (AS-AQ,
4 + 10 mg ⁄ kg ⁄ day, respectively). AS-AQ is a pivotal
artemsinin combination therapy (ACT) in the management
of uncomplicated malaria, available as a fixed combination
(Cuarsucam, Sanofi-Aventis, Paris, France), with more
than 20 million treatments formally documented in the
continent in the last 5 years (WHO 2010).
Amodiaquine is mainly metabolised by the cytochrome
P450 isoform 2C8 (CYP2C8) towards its active metabolite
desethylamodiaquine (DEAQ) (Li et al. 2002), with a
secondary participation of the CYP1A1 and CYP1B1
isoforms (Johansson et al. 2009). AQ-linked severe adverse
side events under prophylaxis regimens are relatively rare
(approximately 1:2000), but serious. These are mainly
associated with netropenia effects, although severe liver
failure has also been described (Jewell et al. 1995; Tingle
et al. 1995; Naisbitt et al. 1997). These events are believed
to appear from the generation of highly reactive, short-
lived quinine-imine (QI) species from the metabolism of
both AQ and DEAQ, albeit to a significantly lesser extent
in the latter. Although these events are relatively rare – and
involving generally higher doses – mild effects are fre-
quently seen in the context of the management of uncom-
plicated forms of the disease, particularly gastrointestinal
effects (reviewed in Gil 2012). Such events (abdominal
pain) have been significantly associated with the presence
of at least one low metaboliser CYP2C8*2 allele in an AQ
monotherapy trial performed in Burkina Faso (Parikh et al.
2007).
Recently, Johansson et al. (2009) provided strong
evidence for a critical role of CYP1A1 and CYP1B1 in the
formation of the toxic QI. The extra-hepatic localisa-
tion of the two enzymes could hence explain the
occurrence of neutropenia because of the transformation
of AQ and DEAQ to QI in, for example the blood, the
location of the majority of serious side effects. Also,
asymptomatic neutropenia is a frequent occurrence in
AQ-based therapies, with unknown long-term conse-
quences in the patient. This raises the possibility that
CYP1A1 and CYP1B1 fast metabolisers are more prone
to AQ therapy side effects.
AS-AQ was introduced in the islands of Zanzibar in
2005 (Bhattarai et al. 2007). In this context, we have
previously analysed the main CYP2C8 polymorphism in
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a cohort of malaria patients in these islands (Cavaco et al.
2005), having identified a non-negligible frequency of
CYP2C8 low activity alleles (3.6%) potentially associated
with an increased risk of occurrence of side effects. Owing
to the potential importance of CYP1A1 and CYP1B1 in
the formation of the QI, we decided to re-visit the previous
study and extend it with a retrospective analysis of the
main mutations in these genes.
Methods
In CYP1A1, we analysed the pivotal I462V SNP
(rs1049843, CYP1A1*2B and *2C) associated with more
active enzymes (increased Vmax) (Cosma et al. 1993). In
CYP1B1, we analysed the variability for eight SNPs [142
C>G (rs10012), 182 G>A (rs28936700), 203 A>G
(rs9282670), 241 T>A (rs9282671), 355 G>T (rs1056827),
4326 C>G (rs1056836), 4360 C>G (rs4986888) and
4390 A>G (rs1800440)] defining the alleles CYP1B1*1, *2,
*3, *4, *5, *6, *7 and *12 (http://www.cypalleles.ki.se/
cyp1b1.htm). In vitro data showed an altered enzyme
activity for the CYP1B1*3, *5, *6 and *7 alleles compared
to CYP1B1*1 (Aklillu et al. 2002; Helmig et al. 2009).
The analysed group of malaria patients was a random
selection from the previously analysed sample for the
CYP2C8 polymorphism (Cavaco et al. 2005), comprising
103 unrelated patients (average age: 2.1 years, SD =
1.2 years, 60 female and 43 male) from the Zanzibar
Islands (Unguja = 44; Pemba = 59). These studies were
ethically cleared by the Zanzibar Medical Research Ethical
Committee (ZAMREC) and the ethics committee of the
Karolinska Institutet.
Peripheral blood samples were collected upon written
informed consent in the local language (Swahili) from the
children’s responsible guardian. DNA was extracted from
the preserved blood samples using the QIAmp DNA
Blood Mini Kit (Qiagen, Hilden, Germany). The analysis
of the CYP1A1 A2455G (I462V) and the CYP1B1
C4326G (L432V), C4360G (A443G) and A4390G
(N453S) were performed through PCR-RFLP methods. For
the determination of the CYP1B1 142 C>G, 182 G>A, 203
A>G, 241 T>A and 355 G>T SNPs, direct PCR amplicon
sequencing was used (Macrogen, Seoul, Korea). DNA
sequence analysis was performed with the Chromas
software (McCarthy, Qld, Australia). Details of primers
and methods can be obtained with the authors.
Results
The CYP1A1*2B ⁄ C alleles are present in the Zanzibar
population at a low combined allelic frequency of 2.4%
(5 ⁄ 206), having been only found in heterozygote form (five
subjects). This confirms the low frequency of this variant in
African native populations previously described Tanzania
with 1.3% and the non-detection in South African Venda
and Zimbabweans (Dandara et al. 2002). In Nigeria, West
Africa, this SNP was as well described as rare (Okobia
et al. 2005). The presence of this SNP in mainland
Tanzanians and in the Zanzibari population, but not in the
other countries, might be related to the fact that in this
Eastern African coastal regions gene mixing may have
existed between the local Black population and the
Orientals, where 2455 A>G was described to be more
frequent (approximately 20%) (Dandara et al. 2002;
Chowbay et al. 2005).
CYP1B1 was analysed for eight SNPs. Three were
determined by PCR-RFLP (4326 C>G, 4360 C>G and
4390 A>G) all located in the region coding the catalyt-
ically important haem-binding domain of the enzyme
(Bailey et al. 1998). From the five SNPs analysed through
sequencing, 142 C>G and 355 G>T were described as
not altering the catalytic properties and protein stability
of CYP1B1 (McLellan et al. 2000); the 182 G>A, 203
A>G and 241 T>A SNPs have not been yet characterised.
Owing to results in the sequencing that did not allow
the unequivocal identification of the genotype (multiple
SNP heterozygoty in three of the SNPs), some subjects
had to be excluded, and the group shrank to 88
individuals.
The above-mentioned SNPs define the alleles
CYP1B1*1, *2, *3, *4, *5, *6, *7 and *12, all present
in the studied population (Table 1), except for the
CYP1B1*5 and CYP1B1*12. The 203 A>G and 241
T>A SNPs, not part of a haplotype (http://www.cypalleles.
ki.se/cyp1b1.htm), were not found in our study. From
the different possible genotypes, CYP1B1*2 ⁄ *6 and
CYP1B1*6 ⁄ *6 are the most frequent (Table 1),
resulting in a high frequency of CYP1B1*2 and *6,
which together comprise about two-thirds of all the
detected alleles.
There is very limited information on the CYP1B1 in
African native populations, a study in an Ethiopian
population being until now the only available report
(Aklillu et al. 2002). Although both being of East African
origin, we observed significant allele prevalence differences
between the two populations. The most frequent alleles
in the Zanzibari islands are CYP1B1*6 (41.5%) and
CYP1B1*2 (27.3%), while the highest frequency allele
observed among Ethiopians as CYP1B1*3 (39.0%), fol-
lowed by CYP1B1*2 with 36.7%. This study adds to
previous reports on the description of the Zanzibar
population (Cavaco et al. 2005; Ferreira et al. 2008),
making this the pharmacogenetically most well-studied
native African population.
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Discussion
The data obtained in the Zanzibari population show that
CYP1A1*2B ⁄ C allele, associated with a higher enzyme
activity, is present in such low frequencies that will not
play an important role in the appearance of adverse events.
For CYP1B1, we found high frequencies for some of the
alleles studied (*6, *2 and *3). From these, CYP1B1*6 has
been associated with lower enzyme activity (lower Vmax)
and for *2 and *3, enzyme activity was comparable to *1
(Aklillu et al. 2002). The genotypes observed for CYP1B1
may lead to the formation of less QI metabolite and then
to lower risk of adverse events.
Although serious adverse events are rare in the treatment
for uncomplicated malaria, mild events are common. In the
particular case of AQ-based treatments, these have been
consistently reported (Parikh et al. 2007; Ndiaye et al.
2011). From the present knowledge, the most likely genetic
candidates modulating the risk for these events are the
polymorphisms at CYP1A1 and CYP1B1, particularly
when associated with CYP2C8 variability. It is expected
that a CYP2C8 low metaboliser will allow a higher
exposure to AQ, permitting more chances for CYP1A1 ⁄
CYP1B1 to metabolise a fraction of the drug towards the
locally reactive QI.
Considering the characteristics of the Zanzibari popu-
lation, with notable – for African standards – frequencies
of the very low active CYP2C8*3 and *4 alleles, and a
massive exposure to AS-AQ, one would expect the emer-
gence of reports concerning serious AQ-related adverse
events. We speculate that the continuous success and safety
of this drug in the islands might be partially related with
the fact that the frequency of CYP1A1 ⁄ CYP1B1 fast
metabolisers is low, hence lowering the risk of adverse
events. African populations are genetically very diverse
(Lambert & Tishkoff 2009). Our present data should not
be considered as referential for other regions in the
continent, a view supported by documented differences
between Africa countries regarding the frequency of
CYP1A1 alleles (reviewed in Gil 2012). It is likely that
there are presently populations carrying significant fre-
quencies of CYP1A1 and 1B1 fast alleles metaboliser
alleles being targeted with AS-AQ treatments, as this is one
of the most adopted ACTs in Africa. Pharmacogenetic
studies in such regions, focusing on CYP2C8, CYP1A1 and
CYP1B1 polymorphisms, seem warranted.
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Table 1 Genotype and allelic frequencies of CYP1B1
CYP1B1 genotypes (n = 88) Allele frequencies (n = 176)
Genotypes N Frequency (95% CI) Allele (SNPs) N Frequency (95% CI)
*1 ⁄ *1 5 0.057 (0.019–0.128) CYP1B1*1
(none)
18 0.102 (0.058–0.147)
*1 ⁄ *2 4 0.046 (0.13–0.112) CYP1B1*2
(142C>G; 355G>T)
48 0.273 (0.207–0.339)
*1 ⁄ *3 4 0.046 (0.13–0.112) CYP1B1*3
(4326C>G)
28 0.159 (0.105–0.213)
*2 ⁄ *2 10 0.114 (0.056–0.199) CYP1B1*4
(4390A>G)
2 0.011 (0.001–0.041)
*2 ⁄ *4 2 0.023 (0.003–0.080) CYP1B1*6
(142C>G; 355G>T; 4326C>G)
73 0.415 (0.342–0.488)
*2 ⁄ *6 21 0.239 (0.154–0.341) CYP1B1*7
(142C>G; 355G>T; 4326C>G; 4360C>G)
7 0.040 (0.016–0.080)
*2 ⁄ *7 1 0.011 (0.0003–0.062)
*3 ⁄ *3 9 0.102 (0.048–0.185)
*3 ⁄ *6 5 0.057 (0.019–0.128)
*3 ⁄ *7 1 0.011 (0.0003–0.062)
*6 ⁄ *6 23 0.261 (0.173–0.366)
*6 ⁄ *7 1 0.011 (0.0003–0.062)
*7 ⁄ *7 2 0.023 (0.003–0.080)
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